Advanced Ovarian Cancer Clinical Trial
Official title:
Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors
Verified date | May 2014 |
Source | Daiichi Sankyo Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a Phase 1, open label study to assess the safety and tolerability of U3 1565, determine maximum tolerated dose (MTD) or establish maximum administered dose (MAD) safety and tolerability.
Status | Completed |
Enrollment | 36 |
Est. completion date | January 2013 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Pathologically documented advanced solid malignant tumor refractory to standard treatment or for which no standard treatment is available. - Evaluable tumor for all parts of the study and, only for enrollment in Part 2b, measurable tumor per RECIST version 1.1. However, subjects with advanced ovarian cancer may be enrolled in Part 2b even if they do not have a tumor measurable per RECIST version 1.1, as long as they have circulating levels of CA125 higher than 35 U/mL. - Eastern Cooperative Oncology Group (ECOG) performance status =< 1. - Men or women >= 18 years of age. - Willing to provide pre-existing diagnostic or resected tumor samples, such as paraffin embedded sections, if available. - Willing, only for enrollment in Part 2b, to provide tumor biopsies before and after treatment. - For female subjects, is postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile or, if otherwise of childbearing potential, has a negative urine or serum pregnancy test at entry into the study, uses maximally effective birth control during the course of the study, and is willing to use contraception for 6 months following the last study drug administration. - For male subjects, is surgically sterile or willing to use a double barrier contraception method upon enrollment, during the course of the study, and for 6 months following the last study drug administration. - Able to comprehend, sign, and date current Institutional Review Board- (IRB) approved informed consent form (ICF - including Health Insurance Portability and Accountability Act [HIPAA] authorization, if applicable) before performance of any study-specific procedures or tests. Exclusion Criteria: - History of lymphoma, leukemia, or other hematopoietic malignancy. - History of human immunodeficiency virus (HIV) positivity. HIV testing is not required for establishing eligibility. - History of bleeding diathesis. - History of idiosyncratic reactions to antibody drug products. - History of stem cell or bone marrow transplant. - History of myocardial infarction (MI) within 6 months before enrollment, symptomatic congestive heart failure (CHF; New York Heart Association > Class II), unstable angina or unstable cardiac arrhythmia requiring medication - History of clinically significant pulmonary disease after receiving epidermal growth factor receptor- (EGFR) targeting agents. - Any concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor. - Clinically active brain metastases defined as symptomatic or requiring treatment with steroids or anti-convulsants. - Unresolved toxicities from prior anti-cancer therapy defined as toxicities, except alopecia, not yet resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Grade =< 1 or baseline values. Subjects with chronic Grade 2 toxicities may be eligible at the discretion of the Investigator or Sponsor (eg, Grade 2 chemotherapy-induced neuropathy). - Mean QTcF (Fridericia's correction) intervals > 450 msec for male subjects and > 470 msec for female subjects, based on screening electrocardiogram (ECG). - Moderate to severe cardiac valvular abnormalities identified by echocardiography at screening. - Hematological values, as follows: Absolute neutrophil count (ANC) < 1.5 X 109/L Platelet count < 100 X 109/L Hemoglobin (Hb) < 9 g/dL - Renal function, as follows: Creatinine > 1.5 X upper limit of normal (ULN) or creatinine clearance < 60 mL/min, as calculated using the modified Cockcroft Gault equation. - Hepatic function, as follows: Aspartate aminotransferase (AST) > 3 X ULN (if liver metastases are present, > 5 X ULN). Alanine aminotransferase (ALT) > 3 X ULN (if liver metastases are present, >= 5 X ULN) - Bilirubin > 1.5 X ULN - Coagulation function, as follows: Prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5 X ULN - Anti-cancer therapy, including antibody, retinoid, or hormonal treatment, within 3 weeks before enrollment. Prior and concurrent use of hormone replacement therapy, use of gonadotropin-releasing hormone modulators for prostate cancer, and use of somatostatin analogs for neuroendocrine tumors are permitted. - Therapeutic radiation treatment within 4 weeks or palliative radiation treatment within 2 weeks before enrollment, as long as radiation toxicities have resolved to NCI CTCAE grade =< 1 or baseline values. - Major surgery within 4 weeks before enrollment. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Karmanos Cancer Center | Detroit | Michigan |
United States | Sarah Cannon Research Institute | Nashville | Tennessee |
United States | Univ. Oklahoma Health Science Center | Oklahoma City | Oklahoma |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Daiichi Sankyo Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number (percent) of subjects experiencing adverse events (AEs) after treatment with U3-1565 | Number (percent) of subjects experiencing adverse events (AEs) after treatment with U3-1565 | 6 months | No |
Secondary | determine the maximum tolerated dose (MTD) or tolerability of maximum administered dose (MAD). | 12 months | No | |
Secondary | Greatest percent reduction in the sum of longest diameters (SLD) of measurable tumors, if applicable, after U3 1565 treatment | 24 months | No | |
Secondary | Changes in pharmacodynamic biomarkers in blood and other body fluid specimens | Changes in pharmacodynamic biomarkers in blood and other body fluid specimens (such as soluble HB-EGF and CA125 in serum and ascites) and tumor biopsies after U3 1565 treatment. | 24 months | No |
Secondary | Changes in tumor perfusion and vascularity after U3-1565 treatment using Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) | 24 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03611179 -
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06055348 -
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04135521 -
Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
|
||
Completed |
NCT01462149 -
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT03292172 -
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05794659 -
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT04360629 -
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
|
N/A | |
Completed |
NCT00516724 -
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
|
Phase 1 | |
Completed |
NCT03158935 -
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
|
Phase 1 | |
Completed |
NCT05775549 -
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
|
||
Active, not recruiting |
NCT03737643 -
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
|
Phase 3 | |
Recruiting |
NCT04862325 -
SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS
|
N/A | |
Completed |
NCT01989546 -
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
|
Phase 1/Phase 2 | |
Recruiting |
NCT04556539 -
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT03161132 -
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
|
Phase 2 | |
Active, not recruiting |
NCT04065009 -
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
|
Phase 3 | |
Active, not recruiting |
NCT01844986 -
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
|
Phase 3 | |
Not yet recruiting |
NCT05924776 -
Plasmodium Immunotherapy for Advanced Ovarian Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03878849 -
Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
|
Phase 2 |